Our Board of Advisors

IPN is advised by our Board of Advisors, a group of advisors who comprise of seminal leaders contributing to the evolution and expansion of the psychedelic field. The Advisors serve our Team to provide wisdom, intel, and strategic vision for our organization. 

2023-2024 Board of Advisors

Monnica T. Williams, PhD, ABPP

Monnica T. Williams, PhD, ABPP

Professor of Psychology, University of Ottawa; Board-Certified Licensed Clinical Psychologist

Dr. Monnica T. Williams is a board-certified licensed clinical psychologist and Full Professor in the School of Psychology, where she is the Canada Research Chair in Mental Health Disparities. She is also the Clinical Director of the Behavioral Wellness Clinic in Connecticut, where she provides supervision and training to clinicians for empirically-supported treatments. Prior to her move to Canada, Dr. Williams was on the faculty of the University of Pennsylvania Medical School (2007-2011), the University of Louisville (2011-2016), and the University of Connecticut (2016-2019). Dr. Williams’ current projects include the assessment of race-based trauma, unacceptable thoughts in OCD, improving cultural competence in mental health care services, and interventions to reduce racism. This includes her work as a PI in a multisite study of MDMA-assisted psychotherapy for PTSD. She is a member of the Scientific Advisory Board of the International OCD Foundation, and co-founded their Diversity Council. She serves on the editorial board of several academic journals, and has published over 100 scientific articles, primarily on OCD, trauma, and cultural issues.
Cody J. Wenthur, Pharm.D, Ph.D

Cody J. Wenthur, Pharm.D, Ph.D

Assistant Professor - School of Pharmacy, University of Wisconsin - Madison; Founding Director, Transdisciplinary Center for Research in Psychoactive Substances; Psychoactive Pharmaceutical Investigation MS Program

Dr. Cody J. Wenthur is a translational investigator in the Department of Pharmacy Practice and Translational Medicine at UW–Madison, serves as the founding director of the MS Program in Psychoactive Pharmaceutical Investigation, and as the chair of education and outreach for the Transdisciplinary Center for Research in Psychoactive Substances. His work is focused on improving our understanding of the basis for beneficial and detrimental effects of psychedelics, opioids, cannabinoids, and other neuroplasticity-inducing approaches in the context of novel therapeutic approaches for promoting and maintaining mental health. His research program has received grant and fellowship support from NIGMS, NIDA, NIMH, independent foundations, industrial partners, and philanthropic funds. The resulting findings have been published in leading journals such as Nature and PNAS, have yielded the development of first-in-class tool compounds, have generated new techniques for the investigation of polypharmacologic effects of complex psychoactive mixtures, and supported improved understanding of extrapharmacolgic factors that impact psychoactive drug effects.

Rick Strassman, MD

Rick Strassman, MD

Adjunct Associate Professor of Psychiatry, University of New Mexico School of Medicine

Rick Strassman, M.D., author of “DMT: The Spirit Molecule,” and co-author of “Inner Paths to Outer Space,” lives in Gallup, New Mexico, and is Clinical Associate Professor of Psychiatry at the University of New Mexico School of Medicine. A native of Los Angeles, his undergraduate studies occurred at Pomona College and Stanford University, medical training at Albert Einstein College of Medicine of Yeshiva University, psychiatry residency at UC Davis, and psychopharmacology fellowship at UC San Diego. He performed the first new human research with hallucinogenic drugs in the U.S. in a generation. In “DMT and The Soul of Prophecy” (Inner Traditions), and has developed a new top-down model of religious/prophetic experience, “theoneurology.” This new model provides a theistic complement to that of the reigning materialistic bottom-up neurotheology. His website is www.rickstrassman.com

Kwasi Adusei, DNP, PMHNP-BC

Kwasi Adusei, DNP, PMHNP-BC

Senior Prescriber and Clinical Liaison, Journey Clinical

Dr. Kwasi Adusei is a service-oriented, curious Ghanaian native passionate about the intersections of community, well-being, and technology. He has a vision for a future driven by inner and outer restoration and how they converge to alter the maladaptive systems of our current world. He is a psychiatric mental health nurse practitioner, co-founder of the Psychedelic Society of Western New York, and led the development of a grassroots psychedelic harm reduction organization called the Sanctuary Project. As an educator and community organizer, he is informed by his experience with the war on drugs and community mental health, both as a patient and a clinician. He serves on the boards of Reconsider, the Source Research Foundation, the Psychedelic Medicine Association, and the Psychedelic Research And Training Institute, and is part of the Diversity Working Group for MAPS and an adjunct at the California Institute of Integral Studies.

Ruth Gaviria

Ruth Gaviria

Brand and Marketing Strategy Consultant

Ruth Gaviria is an award-winning leader known for creating and establishing brand and marketing for publicly traded brands and nonprofit organizations. She is considered an expert in brand development, the role of marketing in a changing organization and understanding the consumer voice. Gaviria launched her own brand and marketing consultancy in 2019 and currently works with on tech start-ups, nonprofits, real estate, media and entertainment brands. Previously, Gaviria was Entercom’s (now Audacy) first ever CMO, establishing the practice, and overseeing of all marketing and communications functions including corporate marketing, brand development, ad sales marketing and research, and corporate communications and public relations. Before joining Entercom, Gaviria was Executive Vice President of Corporate Marketing at Univision Communications, where she was responsible for structuring the marketing organization. She began her career in brand management, holding positions at Procter & Gamble, Miller Brewing Company, Colgate Palmolive, and Time Inc. Currently, Gaviria serves on the board of Reconsider and St. Jude Children’s Research Hospital.

Neşe Devenot, Ph.D

Neşe Devenot, Ph.D

Postdoctoral Associate, Institute for Research in Sensing (IRiS), University of Cincinnati; Affiliate Scholar, Center for Psychedelic Drug Research & Education (CPDRE), The Ohio State University

Neşe Devenot, PhD is a Postdoctoral Associate at the University of Cincinnati’s Institute for Research in Sensing, an Affiliate Scholar at The Ohio State University’s Center for Psychedelic Drug Research & Education, and a Research Fellow with Psymposia. She previously completed a postdoctoral fellowship in the Department of Bioethics at the Case Western Reserve University School of Medicine, and she received her Ph.D in Comparative Literature from the University of Pennsylvania. Her scholarship examines bioethical approaches to psychedelic medicine, and she conducts research on the function of metaphor and other literary devices in narrative accounts of psychedelic experiences. She was a 2015-16 Research Fellow at the New York Public Library’s Timothy Leary Papers and a Research Fellow with the New York University Psilocybin Cancer Anxiety Study, where she participated in the first qualitative study of patient experiences. She has presented on psychedelics at conferences in the United States, Mexico, Canada, England, France, the Netherlands, and Australia.

Bennet A. Zelner, Ph.D

Bennet A. Zelner, Ph.D

Associate Professor, Robert H. Smith School of Business at the University of Maryland, College Park | Clinical Advisory Board, Usona Institute

Dr. Bennet A. Zelner researches, teaches, and advises on regenerative economics, community well-being production, and the delivery of psychedelic-assisted mental health treatment. He also has a longstanding interest in the process of institutional change, which he previously studied in the context of neoliberal policy reform and the diffusion of Anglo-American shareholder capitalism, and is now examining in relation to the legalization of psychedelic medicines. He serves as Associate Professor of Business and Public Policy at the Robert H. Smith School of Business at the University of Maryland, College Park. In addition to Usona, Bennet advises organizations including Transformative Capital Institute, the Synthesis Institute, Sage Integrative Health, Brooklyn Psychedelic Society, Nautilus Psychedelic Medicine Institute, and Virgils.io. Professor Zelner’s research has appeared in peer-reviewed journals such as the American Sociological Review, Administrative Science Quarterly, Strategic Management Journal, Academy of Management Review, and Research Policy. He has also written for professional and popular audiences in such publications as Harvard Business Review, MAPS Bulletin, and Double Blind. At the Smith School, Professor Zelner teaches classes in economics and global business studies. He also serves as the Academic Coordinator for MBA Global Business Courses and Chairperson of the Teaching Enhancement Committee.

Amelia Laver, LLB(Hons) Dip LPC

Amelia Laver, LLB(Hons) Dip LPC

Attorney at Law | Founder of Psychedelic Network

Past IPN Advisors

Alan K. Davis, Ph.D

Alan K. Davis, Ph.D

Assistant Professor, Psychologist, Director, Center for Psychedelic Drug Research and Education - The Ohio State University and Johns Hopkins University

Dr. Davis is a Clinical Psychologist and the Director of the Center for Psychedelic Drug Research and Education in the College of Social Work at Ohio State University. They are an Assistant Professor of Social Work and Psychiatry at OSU and also on the faculty in the Department of Psychiatry at Johns Hopkins University. Alan has extensive clinical experience working with US Military Veterans and civilians suffering with addiction, PTSD, and depression. Their research explores alternative treatments for addiction and mental illness, including psychedelic-assisted therapies, and how to increase access to current treatment systems through reducing provider stigma about substance misuse and alternative treatment approaches. Alan has published over 80 scientific articles and book chapters and presented research at dozens of national and international scientific conferences. They also published landmark trial in 2021 on the use of psilocybin therapy for depression in JAMA psychiatry. In 2023, they are launching a pilot study of the first psilocybin trial for Veterans with PTSD. Dr. Davis is also the president and founding director of Source Research Foundation.
Manoj Doss, Ph.D

Manoj Doss, Ph.D

Postdoctoral Scholar, Johns Hopkins University School of Medicine

Manoj is a cognitive neuropsychopharmacologist at the Center for Psychedelic and Consciousness Research at Johns Hopkins University. His research is at the intersection of cognitive neuroscience and neuropsychopharmacology with focuses on episodic memory and hallucinogenic drugs. Manoj utilizes complex cognitive paradigms, brain imaging, and computational modelling to explore what makes psychedelics unique compared to other classes of psychoactive drugs in terms of their basic and clinical mechanisms of action. Although Manoj is optimistic that psychedelics will soon have a place in psychiatry, he remains cautious of exaggerated claims and negligence to potential downsides, something he terms ‘psychedelic myopia.’

Want to join our Board of Advisors?

Our appointed board of advisors is composed of experienced psychedelic leaders that provide guidance regarding IPN operations, including semi-annual Board of Advisor Meetings. Below is the list of agreed-upon roles and responsibilities.

If you are able to fulfill the below and would like to support our endeavors in an Advisor capacity, please reach out to us directly at info(at)intercollegiatepsychedelics(dot)net to discuss next steps.

Sign Up as a member today

Ready to Join?

Get access today to our library of content, member events, expansive list of resources and our community/network of students and young professionals in the psychedelic space.

Team          Case Studies          Publications